RedHill Biopharma Ltd. - Special Call Transcript
And we're going to move right on now to our next presenter. It is going to be RedHill Biopharma, and I'd like to introduce Alexandra Okmian and Gilead Raday, and I apologize for the mispronunciation of that, but you're -- both are welcome here, we're glad you're here.
RedHill Biopharma, you have our virtual stage now.
Thank you for joining RedHill's presentation at the MedInvest Virtual Infectious Diseases and Immunology Conference. I will focus today's presentation on RedHill's infectious diseases programs, including our rapidly advancing clinical stage COVID-19 therapeutic development program.
A standard disclaimer. The presentation contains forward-looking statements. In our presentation, no warranty is made to the accuracy or completeness of this presentation.
As for a few corporate highlights. RedHill is an emerging U.S. specialty company. We're primarily focused on U.S. commercialization and developments of drugs for GI diseases and anti-infectives. We have a strong U.S
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |